NAD+ ("NAD+ Peptide"): A Research Review of the Dinucleotide Coenzyme, Its Salvage Pathway and Buffered vs. Unbuffered Formulations

NAD+ (nicotinamide adenine dinucleotide) is the central redox coenzyme of cellular metabolism and the obligatory substrate for the sirtuin, PARP and CD38 enzyme families. Research supplier catalogs list the lyophilized compound as "NAD+ peptide" or "NAD+ 500 mg," and it is filed alongside synthetic research peptides even though it is a dinucleotide, not a peptide at all. This review clarifies that nomenclature, summarizes the biosynthetic and consuming pathways that set cellular NAD+ levels, surveys the principal research domains in which the molecule has been studied, and addresses the formulation and stability chemistry — including the buffered versus unbuffered question — that recurs in laboratory work with the material. All content is provided strictly for research reference.

By Peptide Insider Research Team · 11 min read · Last updated September 4, 2026

On this page

• Introduction
• Biological background: the NAD+ metabolome
• Structure, biosynthesis and mechanism of action
• Evidence by research domain
• NAD+ vs. NMN vs. NR: the precursor comparison
• Formulation and stability: buffered vs. unbuffered NAD+
• Limitations and research considerations
• Where to source for research
• Frequently asked research questions
• Works cited

Introduction

Nicotinamide adenine dinucleotide was identified more than a century ago as the heat-stable "cozymase" required for yeast fermentation, and for most of the twentieth century it was studied almost exclusively as a hydride carrier shuttling electrons between glycolysis, the tricarboxylic acid cycle and the mitochondrial electron transport chain [1,2]. Two discoveries reframed the molecule. First, a family of enzymes — the sirtuins, the poly(ADP-ribose) polymerases (PARPs) and the CD38/CD157 glycohydrolases — was found to consume NAD+ as a substrate rather than merely cycling it between oxidized and reduced states [1,3]. Second, tissue NAD+ content was reported to fall with age in rodents and in human tissue samples, and to be restored by genetic or pharmacological manipulation of the salvage pathway in preclinical models [4,5,6].

Those findings created a laboratory market for the purified compound. Because it is sold lyophilized in vials resembling those of synthetic peptides such as MOTS-c or SS-31, it has acquired the informal label "NAD+ peptide." This review treats NAD+ as a laboratory reference material only.

Biological background: the NAD+ metabolome

NAD+ exists in cells as part of a small, interconnected pool of pyridine nucleotides — NAD+, NADH, NADP+ and NADPH — collectively described as the NAD metabolome [1,7]. The oxidized form NAD+ accepts a hydride ion from substrates in catabolic dehydrogenase reactions to become NADH, which donates electrons to complex I of the respiratory chain. The cytosolic NAD+:NADH ratio is high (reported in the hundreds), while the mitochondrial ratio is far lower, reflecting the compartment's role in oxidative metabolism [2,7]. Total cellular NAD+ concentrations have been reported in the range of roughly 0.2 to 0.5 mM in mammalian cells, with the mitochondrial pool accounting for a substantial share [1,2].

Unlike the redox reactions, which leave the dinucleotide intact, the signaling enzymes cleave the glycosidic bond between nicotinamide and the ADP-ribose moiety. Sirtuins transfer the acetyl (or other acyl) group from a protein lysine to ADP-ribose, releasing nicotinamide and O-acetyl-ADP-ribose; PARPs polymerize ADP-ribose onto target proteins during DNA repair; and CD38 generates cyclic ADP-ribose and ADP-ribose as calcium-mobilizing messengers [1,3,8]. Every one of these reactions liberates nicotinamide, which must be recycled or the pool would collapse. Isotope-tracer flux studies in mice have reported that the entire NAD+ pool of some tissues turns over several times per day, and that PARPs and sirtuins together account for the majority of consumption in cultured cells [9].

The age-associated decline in NAD+ has been attributed less to reduced synthesis than to increased consumption: CD38 expression rises with age, largely on infiltrating immune cells that degrade extracellular NMN [10,11], and in neurons SARM1 has been reported to trigger axon degeneration by locally destroying NAD+ after injury [12].

Structure, biosynthesis and mechanism of action

Structure. NAD+ is composed of two nucleotides joined by their phosphate groups. One nucleotide carries an adenine base; the other carries nicotinamide attached to ribose through a quaternary, positively charged pyridinium nitrogen — the "+" in NAD+. The molecular formula is C₂₁H₂₇N₇O₁₄P₂ and the molecular weight is 663.4 g/mol for the free acid. The pyridinium ring is the reactive centre for hydride transfer (C4 position) and the N-glycosidic bond between nicotinamide and ribose is the site cleaved by the consuming enzymes [1,3].

Biosynthesis. Mammalian cells build NAD+ by three routes [1,2,13]. The de novo pathway converts tryptophan through the kynurenine series to quinolinic acid and then to nicotinic acid mononucleotide; it operates chiefly in liver and kidney. The Preiss–Handler pathway converts nicotinic acid (niacin) to the same intermediate via nicotinic acid phosphoribosyltransferase. The salvage pathway recycles nicotinamide released by the consuming enzymes: nicotinamide phosphoribosyltransferase (NAMPT) converts nicotinamide to NMN, and NMN adenylyltransferases (NMNAT1–3, located in the nucleus, cytosol and mitochondria respectively) adenylate NMN to NAD+. Nicotinamide riboside (NR) enters the salvage pathway via NR kinases, which phosphorylate it to NMN [13,14]. Flux measurements have reported that in most tissues the salvage route predominates and that NAMPT is rate-limiting [9,13].

Mechanism of action as a research compound. NAD+ is not a receptor ligand; it acts as a cosubstrate. Studies that raise the intracellular pool — by NAMPT overexpression, by precursor supply or by inhibiting consumers such as PARP1 or CD38 — have reported increased sirtuin activity (especially SIRT1 and SIRT3), improved mitochondrial respiratory capacity and altered acetylation of metabolic enzymes in cellular and rodent models [3,10,15]. Whether extracellular NAD+ itself enters cells intact remains a topic of active investigation; a proportion is thought to be degraded at the cell surface to NMN and nicotinamide by CD38, CD73 and related ecto-enzymes before uptake, and the presence of dedicated transporters in mammalian plasma membranes is debated [1,11,16].

Evidence by research domain

The NAD+ literature is unusually broad, ranging from decades of enzymology to recent human pharmacokinetic work. The table summarizes the principal research domains and the maturity of the evidence in each.

Human pharmacokinetics

Direct human data on NAD+ itself remain limited. Grant and colleagues conducted a pilot study of a six-hour intravenous NAD+ infusion in a small male cohort and reported no detectable rise in plasma NAD+ or its metabolites during the first two hours, indicating rapid clearance, followed by increased urinary excretion of NAD+ and methylnicotinamide by the end of the infusion [16]. Trammell and colleagues reported that oral nicotinamide riboside raised the blood NAD+ metabolome in mice and in a single-subject human study [19]. Both were small, hypothesis-generating studies.

NAD+ vs. NMN vs. NR: the precursor comparison

Research programs frequently choose among NAD+ itself and its two salvage-pathway precursors, and the literature supports a few points of distinction. NMN (nicotinamide mononucleotide, 334.2 g/mol) is one enzymatic step from NAD+ via NMNAT; NR (nicotinamide riboside, 255.2 g/mol) is two steps away via NR kinases. Liu and colleagues reported in mice that intravenously delivered NR and NMN reached tissues intact, whereas orally delivered precursors were largely converted to nicotinamide in the liver before reaching circulation [9]. Chini and colleagues reported that extracellular NMN is a preferred substrate of the CD38 ecto-enzyme, which degrades it before it can be salvaged [11]. Whether NAD+ itself crosses membranes intact or is first hydrolyzed to NMN and nicotinamide is unresolved [1,16].

Formulation and stability: buffered vs. unbuffered NAD+

A distinctive feature of NAD+ compared with most research peptides is its pH-dependent chemical instability, which is the reason suppliers offer both "unbuffered" and "buffered" lyophilized forms. Lowry, Passonneau and Rock established the fundamental pattern in 1961: oxidized pyridine nucleotides (NAD+, NADP+) are relatively stable in acid but decompose in alkaline solution, whereas the reduced forms (NADH, NADPH) show the opposite behaviour, being labile in acid and stable in base [22]. In neutral-to-alkaline aqueous solution NAD+ degrades by hydrolysis of the nicotinamide–ribose glycosidic bond and by cleavage of the pyrophosphate linkage, yielding nicotinamide, ADP-ribose, AMP and NMN — the same product set generated enzymatically by glycohydrolases and pyrophosphatases [16,21,22].

Unbuffered NAD+. The free acid dissolves to give a strongly acidic solution, because the pyrophosphate protons are readily ionized. Such a solution is chemically the more stable state for the oxidized nucleotide [22], but its low pH is incompatible with most biological assays and cell-culture media, which require adjustment before use.

Buffered NAD+. Buffered preparations are formulated with a base (commonly sodium bicarbonate or a phosphate salt) so that reconstitution yields a solution near physiological pH. This convenience comes at a chemical cost: at pH 7–8 the oxidized nucleotide is in the regime where alkaline degradation begins, so buffered solutions have a shorter useful life and are more sensitive to temperature and time than acidic stocks [22]. Analytical methods papers accordingly recommend preparing NAD+ working solutions fresh, keeping them cold, and quantifying by HPLC with UV detection at 260 nm or by LC-MS/MS rather than assuming nominal concentration [21].

Limitations and research considerations

• Nomenclature confusion. "NAD+ peptide" is a marketing label. Literature searches using that phrase return almost nothing; researchers should search for "nicotinamide adenine dinucleotide," "NAD metabolism" or the specific precursor of interest.
• Precursor versus NAD+. The large majority of interventional animal studies used NMN or NR, not NAD+ itself. Extrapolating precursor findings to the dinucleotide assumes intact uptake, which has not been established [1,9,16].
• Chemical instability. Nominal concentrations of aqueous NAD+ stocks drift with time, temperature and pH. Analytical confirmation is advisable for quantitative work [21,22].
• Human evidence. Human data on NAD+ itself are limited to small pharmacokinetic pilots; no conclusions about physiological outcomes can be drawn from them [16,19].

Where to source for research

Lyophilized NAD+ is available from several research-compound suppliers, typically in vials labelled by mass (for example, "NAD+ 500 mg") and in buffered or unbuffered form. Research-grade material can be sought from suppliers such as Short Chain Aminos, BioPep, Catalyst Research and Apex Research Services; catalog availability, formulation (buffered or free acid) and accompanying analytical documentation vary by supplier and by lot. When comparing lots, laboratories should request HPLC purity data, confirmation of whether the material is the free acid or a buffered formulation, water content, and storage history, since these variables determine the usable concentration of a reconstituted stock. Our guide to evaluating research peptide suppliers and the suppliers directory outline the documentation to expect. All material is intended for research use only.

Frequently asked research questions

Is NAD+ actually a peptide?

No. NAD+ is a dinucleotide — nicotinamide riboside and adenosine joined by a pyrophosphate bridge — with no amino acids and no peptide bond. The label "NAD+ peptide" arises because research suppliers sell it as a lyophilized powder alongside genuine peptides. Chemically and analytically it belongs to the pyridine nucleotide family, not to peptides.

What is the difference between buffered and unbuffered NAD+?

Unbuffered NAD+ is the free acid, which dissolves to a strongly acidic solution in which the oxidized nucleotide is chemically most stable. Buffered NAD+ includes a base, usually bicarbonate or phosphate, so reconstitution gives a near-neutral solution that is assay-compatible but degrades faster, because NAD+ is labile under alkaline conditions.

Why does NAD+ decline with age in research models?

Studies attribute the decline mainly to increased consumption rather than reduced synthesis. CD38 expression rises with age, especially on infiltrating immune cells, and PARP activity increases with accumulating DNA damage; both consume NAD+ and its precursor NMN, while salvage capacity via NAMPT does not keep pace.

How does NAD+ differ from NMN and NR?

NMN and NR are salvage-pathway precursors one and two enzymatic steps upstream of NAD+. Mouse tracer studies reported that oral precursors are largely converted to nicotinamide in the liver, while intravenous forms reach tissues intact. Whether NAD+ itself crosses cell membranes intact remains unresolved in the literature.

How is NAD+ measured in laboratory samples?

Validated approaches include reversed-phase HPLC with UV detection at 260 nm, LC-MS/MS for NAD+ together with NMN, NR and nicotinamide, and enzymatic cycling assays. Because the compound degrades in neutral or alkaline solution, methods papers recommend rapid extraction under cold acidic conditions and fresh standard preparation.

Works cited

1. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–141. doi:10.1038/s41580-020-00313-x. PMID 33353981.
2. Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr. 2008;28:115–130. doi:10.1146/annurev.nutr.28.061807.155443. PMID 18429699.
3. Cantó C, Menzies KJ, Auwerx J. NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 2015;22(1):31–53. doi:10.1016/j.cmet.2015.05.023. PMID 26118927.
4. Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357. doi:10.1371/journal.pone.0042357. PMID 22848760.
5. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208–1213. doi:10.1126/science.aac4854. PMID 26785480.
6. Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795–806. doi:10.1016/j.cmet.2016.09.013. PMID 28068222.
7. Xiao W, Wang RS, Handy DE, Loscalzo J. NAD(H) and NADP(H) redox couples and cellular energy metabolism. Antioxid Redox Signal. 2018;28(3):251–272. doi:10.1089/ars.2017.7216. PMID 28648096.
8. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464–471. doi:10.1016/j.tcb.2014.04.002. PMID 24786309.
9. Liu L, Su X, Quinn WJ, et al. Quantitative analysis of NAD synthesis-breakdown fluxes. Cell Metab. 2018;27(5):1067–1080.e5. doi:10.1016/j.cmet.2018.03.018. PMID 29685734.
10. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 2016;23(6):1127–1139. doi:10.1016/j.cmet.2016.05.006. PMID 27304511.
11. Chini CCS, Peclat TR, Warner GM, et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels. Nat Metab. 2020;2(11):1284–1304. doi:10.1038/s42255-020-00298-z. PMID 33199925.
12. Gerdts J, Brace EJ, Sasaki Y, DiAntonio A, Milbrandt J. SARM1 activation triggers axon degeneration locally via NAD+ destruction. Science. 2015;348(6233):453–457. doi:10.1126/science.1258366. PMID 25908823.
13. Yoshino J, Baur JA, Imai S. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018;27(3):513–528. doi:10.1016/j.cmet.2017.11.002. PMID 29249689.
14. Cantó C, Houtkooper RH, Pirinen E, et al. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012;15(6):838–847. doi:10.1016/j.cmet.2012.04.022. PMID 22682224.
15. Bai P, Cantó C, Oudart H, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 2011;13(4):461–468. doi:10.1016/j.cmet.2011.03.004. PMID 21459330.
16. Grant R, Berg J, Mestayer R, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci. 2019;11:257. doi:10.3389/fnagi.2019.00257. PMID 31572323.
17. Braidy N, Guillemin GJ, Mansour H, Chan-Ling T, Poljak A, Grant R. Age related changes in NAD+ metabolism, oxidative stress and Sirt1 activity in Wistar rats. PLoS One. 2011;6(4):e19194. doi:10.1371/journal.pone.0019194. PMID 21541336.
18. Fang EF, Scheibye-Knudsen M, Brace LE, et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD+/SIRT1 reduction. Cell. 2014;157(4):882–896. doi:10.1016/j.cell.2014.03.026. PMID 24813611.
19. Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. doi:10.1038/ncomms12948. PMID 27721479.
20. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529–547. doi:10.1016/j.cmet.2018.02.011. PMID 29514064.
21. Yoshino J, Imai S. Accurate measurement of nicotinamide adenine dinucleotide (NAD+) with high-performance liquid chromatography. Methods Mol Biol. 2013;1077:203–215. doi:10.1007/978-1-62703-637-5_14. PMID 24014411.
22. Lowry OH, Passonneau JV, Rock MK. The stability of pyridine nucleotides. J Biol Chem. 1961;236:2756–2759. PMID 14466980.

Explore related compounds: MOTS-c · SS-31 (elamipretide) · 5-Amino-1MQ and NNMT · Glutathione (GSH) · Epithalon